RxDoctor Payments Data

Yasir Akhtar, MD

Interventional Cardiology · Powell, TNNPI 1013001098

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (30.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Angiodynamics, Inc. at 34.9% of the total. 2025 is the largest year on record at $21,515, 4.6 times the $4,695 reported in 2019.

$69,617in general payments, 2019–2025

Across 550 payments — averaging $126.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$24K
  • Livanova USA, Inc.$12K
  • Penumbra, Inc.$7K
  • Medtronic$6K
  • Boston Scientific$5K
  • Edwards Lifesciences$3K
  • plus $12K from 39 others

What the payments were for

  • Consulting fees$2,4003%
  • Speaking & faculty fees$13,15019%
  • Travel & lodging$15,71423%
  • Food & beverage$17,08225%
  • Education$220%
  • Other$21,25031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,617 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$304,323
Medicare patients
399
Services billed
1,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten11$90,566
EliquisApixaban74$73,583
XareltoRivaroxaban32$36,372
Repatha SureclickEvolocumab29$28,577
BrilintaTicagrelor27$18,722
JardianceEmpagliflozin11$18,466
EntrestoSacubitril/Valsartan26$17,291
Prasugrel Hcl27$3,279
Bumetanide35$2,164
ClopidogrelClopidogrel Bisulfate221$1,871
Ranolazine ErRanolazine22$1,589
Potassium Chloride100$1,518
Atorvastatin Calcium94$1,275
Amiodarone Hcl13$996
Rosuvastatin Calcium39$778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$359$90,56611 claims
PfizerEliquis$121$73,58374 claims
Johnson & JohnsonXarelto$199$36,37232 claims
AstraZenecaBrilinta$426$18,72227 claims
Boehringer IngelheimJardiance$34$18,46611 claims
NovartisEntresto$276$17,29126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Powell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →